查找相似内容

🚨 Just had an intriguing discovery at the Blokhin Institute in Moscow, Russia. While waiting for my doctor's appointment, I decided to explore the institute's museum. Among the exhibits, I stumbled upon a personal letter and invitation from Edward Kennedy to one of the institute's doctors. This was during the Cold War era, which makes this find even more fascinating. It seems that even amidst political tensions, there was recognition of the significant contributions Russia has made to arts and sciences. This glimpse into history reminds us of the importance of collaboration in fields like medicine, where advancements benefit everyone, regardless of borders. #BlokhinInstitute#ColdWarHistory#MedicalResearch#InternationalCollaboration#RussianAchievements

Tessera Therapeutics Secures $50M Tessera Therapeutics has raised $50 million in funding on December 18, 2024. The early-stage life sciences company is at the forefront of Gene Writing™, a cutting-edge biotechnology aimed at transforming medicine and scientific research. More details available on their official website: Tessera Therapeutics #TesseraTherapeutics#Funding#LifeSciences#Biotechnology#GeneWriting#Healthcare#MedicalResearch

$140M Funding for Ottimo Pharma Ottimo Pharma announces a funding round of $140 million set for December 19, 2024. The company focuses on developing bi-functional medicines aimed at improving the lives of individuals living with cancer. Learn more #Funding#OttimoPharma#Cancer#BiFunctionalMedicines#Healthcare#Pharmaceuticals#LifeSciences#Investments#MedicalResearch#Oncology#HealthTech#Biotechnology

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

$60M Funding for Psioxus Psioxus Therapeutics has successfully secured $60M in funding as part of its latest round, scheduled for December 17, 2024. This funding aims to advance its innovative tumor gene therapy platform focused on improving cancer treatment outcomes. #Funding#Cancer#Biotech#Oncology#GeneTherapy#Therapeutics#ClinicalStage#Investment#Healthcare#Psioxus#AkamisBio#Tumor#LifeScience#MedicalResearch#Therapy#Innovative#Impact#Technology#Platform